Sign up to save your podcasts
Or
Share Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis
CME credits: 0.75
Valid until: 24-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/collaborative-consult-cases-patient-reflection-and-discussions-whats-new-in-pediatric-atopic-dermatitis/13982/
Over 9.8% of children in the US have atopic dermatitis (AD), which is associated with significant disability and poor quality of life. While progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD, challenges still exist, including lack of prescriber confidence due to unfamiliarity of mechanisms of action of new and emerging agents.
This activity, with expert faculty Dr. Anthony Mancini, will explore AD pathophysiology, review newly approved therapies and their place in treatment, and will present the latest on emerging agents, along with a patient ambassador sharing their experience with AD.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.75
Valid until: 24-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/collaborative-consult-cases-patient-reflection-and-discussions-whats-new-in-pediatric-atopic-dermatitis/13982/
Over 9.8% of children in the US have atopic dermatitis (AD), which is associated with significant disability and poor quality of life. While progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD, challenges still exist, including lack of prescriber confidence due to unfamiliarity of mechanisms of action of new and emerging agents.
This activity, with expert faculty Dr. Anthony Mancini, will explore AD pathophysiology, review newly approved therapies and their place in treatment, and will present the latest on emerging agents, along with a patient ambassador sharing their experience with AD.
=